Zentalis Pharmaceuticals (ZNTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Zentalis Pharmaceuticals’ strategic advancements and promising clinical outcomes. The company has sharpened its clinical strategy with the azenosertib franchise, particularly in treating Cyclin E1+ platinum-resistant ovarian cancer, a subset with significant unmet needs. The ongoing DENALI Part 2a trial, which is pivotal for the company’s future, is designed to confirm optimal dosing and is aligned with FDA requirements, indicating a potential path for accelerated approval.
Furthermore, Zentalis has demonstrated consistent efficacy signals across trials, with notable objective response rates and progression-free survival metrics that surpass historical benchmarks for similar treatments. The company’s cash runway extending into late 2027 provides financial stability, allowing it to focus on advancing its biomarker-driven franchise. These factors collectively position Zentalis well for future growth, justifying the Buy rating.
In another report released on May 15, Oppenheimer also reiterated a Buy rating on the stock with a $9.00 price target.
ZNTL’s price has also changed dramatically for the past six months – from $3.470 to $1.260, which is a -63.69% drop .